Literature DB >> 7472824

Final height after long-term growth hormone treatment in Turner syndrome. European Study Group.

J Van den Broeck1, G G Massa, A Attanasio, A Matranga, J L Chaussain, D A Price, D Aarskog, J M Wit.   

Abstract

OBJECTIVES: To study final height after long-term growth hormone (GH) treatment in girls with Turner syndrome (TS). PATIENTS: One hundred fifty three patients with TS, participating in five European trials, were included. They started GH treatment in 1987-1989 at an age of 10 years or older. Mean age at start of treatment ranged between 11.7 and 14.6 years among countries and mean bone age between 9.4 and 11.8 years. Fourteen girls were lost to follow-up, leaving 139 for analysis. Most girls have now attained final height (FH), defined as a linear growth velocity (GV) of 4 mm/yr or less, measured over at least 6 months (group 1, n = 56), or near-FH, defined as a GV of 5 to 9 mm/yr (group 2, n = 22). Sixty-one girls were still growing 10 mm/yr or more. METHODS AND MAIN
RESULTS: At the last measurement, mean (SD) height was 150.7 (4.9) cm in group 1 and 148.5 (5.1) cm in group 2. The differences between FH and projected final height based on extrapolation of the initial height-standard deviation score on Turner syndrome reference values, were 2.9 (3.8) and 3.0 (3.3) cm, respectively. The mean gain over the Bayley-Pinneau prediction of FH was 3.3 (3.9) cm in both groups. No significant differences between countries were found. The range of gains over projected height (-4.7 to 12.1 cm) was large, and 25% of gains were 5 cm or more. Gain over initial projection was strongly related to initial growth delay and to growth response during the first 2 years of treatment. A logistic regression model is presented that predicts gain of more than 5 cm with a positive predictive value of 62% and a negative predictive value of 84%.
CONCLUSIONS: Long-term GH treatment in girls with TS, starting treatment at a relatively advanced age ( > 10 years) resulted in a modest mean gain in FH of 3 cm, with wide interindividual variation.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7472824     DOI: 10.1016/s0022-3476(95)70161-3

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  16 in total

Review 1.  Long-term results of growth hormone therapy in Turner syndrome.

Authors:  J H Bramswig
Journal:  Endocrine       Date:  2001-06       Impact factor: 3.633

2.  Predicting response to growth hormone treatment.

Authors:  Leena Patel; Peter E Clayton
Journal:  Indian J Pediatr       Date:  2011-11-22       Impact factor: 1.967

Review 3.  Turner syndrome and GH treatment: the state of the art.

Authors:  A M Pasquino
Journal:  J Endocrinol Invest       Date:  2004-12       Impact factor: 4.256

4.  Adult height in sixty girls with Turner syndrome treated with growth hormone matched with an untreated group.

Authors:  A M Pasquino; I Pucarelli; M Segni; L Tarani; V Calcaterra; D Larizza
Journal:  J Endocrinol Invest       Date:  2005-04       Impact factor: 4.256

Review 5.  The use of somatropin (recombinant growth hormone) in children of short stature.

Authors:  Ameeta Mehta; Peter C Hindmarsh
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

Review 6.  Advances in endocrinology.

Authors:  P E Clayton; V Tillmann
Journal:  Arch Dis Child       Date:  1998-03       Impact factor: 3.791

7.  Final Adult Height after Growth Hormone Treatment in Patients with Turner Syndrome.

Authors:  Jung Min Ahn; Jung Hwan Suh; Ah Reum Kwon; Hyun Wook Chae; Ho-Seong Kim
Journal:  Horm Res Paediatr       Date:  2019-09-03       Impact factor: 2.852

8.  A decade of growth hormone treatment in girls with Turner syndrome in the UK. UK KIGS Executive Group.

Authors:  P R Betts; G E Butler; M D Donaldson; D B Dunger; D I Johnston; C J Kelnar; J Kirk; D A Price; P Wilton
Journal:  Arch Dis Child       Date:  1999-03       Impact factor: 3.791

9.  Final height in girls with Turner's syndrome treated with once or twice daily growth hormone injections. Dutch Advisory Group on Growth Hormone.

Authors:  T C Sas; S M de Muinck Keizer-Schrama; T Stijnen; A van Teunenbroek; A C Hokken-Koelega; J J Waelkens; G G Massa; T Vulsma; W J Gerver; H M Reeser; H E Delemarre-van de Waal; M Jansen; S L Drop
Journal:  Arch Dis Child       Date:  1999-01       Impact factor: 3.791

Review 10.  Growth hormone treatment in children: review of safety and efficacy.

Authors:  Mark Harris; Paul L Hofman; Wayne S Cutfield
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.